Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3 studies found for:    TB-403
Show Display Options
Rank Status Study
1 Completed Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
Condition: Solid Tumors
Intervention: Biological: TB-403
2 Recruiting A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Condition: Relapsed or Refractory Medulloblastoma (MB) (Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS))
Interventions: Drug: TB-403 20mg/kg;   Drug: TB-403 50mg/kg;   Drug: TB-403 100mg/kg;   Drug: TB-403 ≤175mg/kg
3 Withdrawn 89Zr-RO5323441 PET Imaging in Glioblastoma
Condition: Glioblastoma
Intervention: Radiation: Molecular imaging with 89Zr-RO5323441

Study has passed its completion date and status has not been verified in more than two years.